We have previously shown that recombinant Sendai virus (SeV) vector, derived from murine parainfluenza virus, is one of the most efficient vectors for airway gene transfer. We have also shown that SeV-mediated transfection on second administration, although reduced by 60% when compared with levels achieved after a single dose, is still high because of the efficient transfection achieved by SeV vector in murine airways. Here, we show that these levels further decrease on subsequent doses. In addition, we validated SeV vector repeat administration in a non-natural host model, the sheep. As part of these studies we first assessed viral stability in a Pari LC Plus nebuliser, a polyethylene catheter (PEC) and the Trudell AeroProbe. We also compared the distribution of gene expression after PEC and Trudell AeroProbe administration and quantified virus shedding after sheep transduction. In addition, we show that bronchial brushings and biopsies, collected in anaesthetized sheep, can be used to assess SeV-mediated gene expression over time. Similar to mice, gene expression in sheep was transient and had returned to baseline values by day 14. In conclusion, the SeV vector should be strongly considered for lung-related applications requiring a single administration of the vector even though it might not be suitable for diseases requiring repeat administration.
INTRODUCTION
Sendai virus (SeV), a murine paramyxovirus, is one of the most efficient viral vectors for airway gene transfer. 1, 2 SeV carrying the cystic fibrosis (CF) transmembrane conductance regulator cDNA is able partially to correct the characteristic CF transmembrane conductance regulator-dependent chloride transport defect in the nasal epithelium of CF knockout mice. 3 Several aspects of SeV biology may explain the high gene transfer efficiency into airway epithelial cells. Moreover, SeV uses cholesterol and sialic acid as receptors and both are present on the surface of most cell types. Further, SeV requires short contact time with the target cell for internalization, and replicates in the cytoplasm of transduced cells, circumventing the nuclear membrane barrier. In mice gene expression is transient, with peak expression approximately 48 h after transfection, generally returning to baseline values within 2 weeks of transfection. 1 A transmission-incompetent SeV vector has been developed by deleting the F-protein, which is essential for cellular entry of the viral genome (DF/SeV). 4 Moreover, this modification does not reduce transfection efficiency of the virus. 1, 4 In general the level of transgene expression achieved from repeat delivery of a viral vector is greatly reduced when compared with that from a single dose due to induction of effective immune responses in the recipient. 5, 6 We have previously shown that SeV-mediated gene expression is reduced by 60% on second dose, and that tolerization of mice against immune-dominant SeV epitopes does not improve efficacy. 7 However, given the extremely high transfection efficiency of SeV, the levels of gene expression achieved after repeat administration may still be of sufficient therapeutic value, if retained on subsequent administrations. Here, we assessed SeV-mediated transfection efficiency after three doses of the virus and compared residual levels of gene expression with that achieved using plasmid DNA complexed to the cationic lipid GL67A, currently being used in a clinical trial by the UK CF Gene Therapy Consortium (http://www.cfgenetherapy.org.uk/).
The vast majority of repeat administration studies have been performed in mouse inbred strains, such as Balb/C and C57BL/6. Given that SeV has a natural tropism for the murine lung leading to pneumonia, we were concerned that assessment of repeat administration in mice may not be representative of non-natural host models, including man. The greater degree of similarity in size, structure and physiology between the sheep and human lung led us to develop sheep as an intermediate model for airway gene transfer, 8 to bridge the gap between studies in rodents and the clinic. Here, we have also assessed the transduction efficiency of both single and repeat SeV vector administration in the ovine lung.
RESULTS

Levels of gene expression after repeat administration of DF/SeV
with short-term intervals to mouse lung are similar to non-viral gene transfer We have previously shown that SeV-mediated transfection on second administration, although reduced by 60% when compared with levels achieved after a single dose, 7 is still high because of the efficient transfection achieved by SeV vector in murine airways. Here, we assessed whether these residual levels are maintained on subsequent dosing. Murine lungs were transfected with three doses (10 8 cell infectious unit (CIU)/mouse/dose) of transmission-incompetent DF/SeV at either weekly or monthly intervals by nasal sniffing. To circumvent generation of anti-reporter gene immune responses, a vector without a reporter gene (DF/SeV-empty) was administered for the first two doses. A vector carrying a luciferase reporter gene (DF/SeV-luc) was administered as the third dose, and luciferase (luc) expression was quantified 2 days after administration (n¼16-19/ group). Luc expression was compared with mice receiving only a single dose of virus (n¼20), mice transfected with the non-viral vector GL67A complexed to pCIK-Lux (n¼19) and phosphatebuffered saline (PBS)-treated negative control mice (n¼10). Gene expression after 3 weekly or monthly, doses was significantly (Po0.001) reduced by 3 to 4 logs compared with mice receiving only one dose, but was significantly (Po0.05) higher than the negative controls ( Figure 1 ). Residual expression levels after three doses of DF/SeV were not significantly different to non-viral transfection ( Figure 1 ).
SeV viability in the Trudell AeroProbe catheters is suitable for in vivo administrations
We next assessed transfection efficiency and repeat administration in sheep for which the virus does not have a natural tropism. In preparation for the in vivo sheep experiments, we first assessed DF/SeV viability in a Pari LC Plus nebuliser, which we routinely use for nonviral gene transfer in sheep. We assessed viability by either collecting DF/SeV aerosol at the end of the Pari LC Plus mouth-piece (as used in man) or at the end of an endotracheal tube (as used for sheep nebulization studies). DF/SeV viability was reduced to less than 1% in the 'mouth-piece' set-up and dropped to less than 0.01% when connected to an endotracheal tube (three independent experiments). This delivery method was, therefore, not used in any further study.
We next assessed virus viability in a polyethylene catheter (PEC), which can be fed through the biopsy channel of a bronchoscope and used to administer virus as a bolus into specific lung segments, and a Trudell AeroProbe catheter, which can be positioned within the trachea or bronchi and generates an aerosol at the tip. Virus viability was 100 and 49 ± 3% in the PEC and AeroProbe, respectively (three independent experiments/condition).
PEC and AeroProbe administration of DF/SeV-LacZ leads to wide-spread b-gal expression in the sheep lung but the distribution pattern varies DF/SeV-LacZ (3.4Â10 9 CIU/sheep. in 5 ml, n¼3 sheep) was first administered by PEC as a bolus into a single lung segment. Gene expression was visualized with X-gal staining 48 h after transfection. High level, but patchy, transfection was seen in the lung possibly due to uneven vector distribution and pooling of the bolus volume compatible with catheter-based delivery (Figure 2a ). Using segmental instillation the adjacent lung segments showed no evidence of transgene expression (Figure 2b ).
We next administered DF/SeV-LacZ using the Trudell AeroProbe to either a single lung segment (10 10 CIU per sheep in 5 ml, n¼1) or the whole lung (4Â10 10 CIU per sheep in 24 ml, n¼1). When directed into a single segment we observed spill over to the adjacent segment on the same (Figures 2c and d) , but not to the contralateral side, of the lung (data not shown). This is likely due to a combination of pooling of the aerosol following impaction on the airway walls close to the tip of the catheter and the fact that the bronchoscope is not wedged in the airway. Figures 2e and f demonstrates deposition of aerosol on airway bifurcations and, interestingly, within a sub-mucosal gland and duct.
With the Trudell AeroProbe positioned in the trachea we observed more even, wide-spread distribution throughout the lung and less of a pooling effect, likely due to the AeroProbe tip not being so close to airway walls (Figure 2g ). The Trudell AeroProbe was, therefore, used for subsequent experiments.
Infectious virus shedding does not occur after DF/SeV transfection Infectious virus shedding after sheep transfection would be a concern, because both the environment and the operators would require protection from exposure to virus. We, therefore, determined whether virus shedding had occurred. Nasal and oral swabs, bronchoalveolar lavage fluid and lung tissues were collected 48 h after transfection with DF/SeV-LacZ (10 10 CIU in 24 ml per sheep, n¼5 sheep). Three plates were analyzed per sample per sheep. Virus spiked positive controls and untreated samples were analyzed in parallel. A small number of Xgal-positive cells (one to three cells per plate) were detected in the collected fluids and tissues of transfected sheep, but these were also present in the untreated controls. In a second group of animals (n¼3) sampled in vivo 48 h post-administration we saw no X-gal-positive cells from oral or nasal swabs, broncho-alveolar lavage fluid or serum samples. We conclude that infectious virus shedding does not occur at a detectable level at 48 h post-transfection.
Bronchial brushings and biopsies can be used to assess SeV-mediated transfection Although LacZ is a useful reporter gene to visualize gene expression histologically, we were not certain whether b-gal expression would be Validation of recombinant Sendai virus in sheep U Griesenbach et al quantifiable in bronchial brushings and biopsies, used to assess duration of gene expression in vivo. We, therefore, collected bronchial brushings (n¼4/sheep) and biopsies (n¼4/sheep) before transfection, then administered DF/SeV-LacZ (10 10 CIU in 24 ml/sheep, n¼3 sheep) and collected bronchial brushings and biopsies (n¼4 each for one sheep, n¼8 each for the other two sheep) and tissue pieces at necropsy 48 h post transfection. Using a chemiluminescent b-gal assay we were able to detect robust levels of b-gal in cell lysates prepared from Figure 2 b-gal expression in sheep lung 2 days after transfection with DF/SeV-LacZ delivered with either a polyethylene catheter (PEC) or the Trudell AeroProbe. DF/SeV-LacZ was administered to a single segment of the sheep lung with a PEC (3.4Â10 9 CIU/sheep in 5 ml, n¼3 sheep). High level, but patchy, gene expression was seen in the treated segment (a), but not in the adjacent segment (b). DF/SeV-LacZ was administered to a single segment using the Trudell AeroProbe (10 10 CIU/sheep in 24 ml, n¼1). Gene expression was visible in the treated, as well in the adjacent segment (c, d). In addition b-gal expression was detected on airway bifurcations and within a sub-mucosal glands (e, f). DF/SeV-LacZ was administered to a whole lung using the Trudell AeroProbe (4Â10 10 CIU/sheep in 24 ml, n¼1) and wide-spread even distribution throughout the lung was observed (g). Representative images are shown. Each side received a dose of 5Â10 9 CIU in 7 ml (n¼4 sheep) and bronchial biopsies were collected 2, 14, 28 and 56 days after transfection (n¼8/sheep/time point) to follow gene expression over time by comparison with pre-treatment biopsies (n¼6/sheep). Similar to mice, the expression was transient and had returned to baseline values by day 14 ( Figure 3 ).
Reduced expression from repeat administration of DF/SeV in sheep
To determine the efficacy of repeat administration, sheep were transfected with three doses (10 10 CIU/sheep/dose) of DF/SeV at monthly intervals. To circumvent generation of anti-reporter gene immune responses DF/SeV-empty was administered for the first two doses. DF/SeV-LacZ was administered as the third dose and b-gal expression was quantified in bronchial biopsies (n¼20/sheep) 2 days after the final administration. A negative control group was treated with three doses of DF/SeV-empty (n¼4 sheep/group). Although we detected some residual expression in one sheep (Po0.05), overall there was no evidence that re-administration of SeV into sheep is feasible ( Figure 4) . We, therefore, concluded that monthly re-administration of DF/SeV in sheep results in a similar loss of efficiency as we observed in mice. For comparison, GL67-mediated non-viral gene transfer does not lead to detectable levels of reporter protein expression in sheep bronchial biopsies or brushings (data not shown).
DISCUSSION
SeV and the modified transmission incompetent DF/SeV are one of the most efficient gene transfer agents for airway epithelial cells, but here we show that repeat administration (three doses at short-term intervals) into mice, which is the natural host, is inefficient. In addition, we optimized SeV-mediated gene transfer into sheep lung for which the virus has no natural tropism, achieving efficient transduction. However, as in mice, repeat administration was unable to achieve the high levels of gene transfer that could be demonstrated following a single dose. Reports on repeat administration of adenovirus or adeno-associated virus to the lungs vary, with some studies reporting successful re-administration, 9-11 whereas other studies failed to detect gene expression after repeat administration. 6, 12 Differences are likely due to different models being used, as well as different number of doses being administered. In some publications, single-dose controls are also missing, which makes an assessment of efficacy after repeated administration difficult. 10 The number of repeat administrations (two vs three) is an important variable when performing and interpreting the efficacy of repeat-dose virus administration. Several population vaccination programmes, for example, human papillomavirus and hepatits A vaccine, require a three-dose schedule. In the context of virusmediated gene transfer, it is feasible that the immune system may not be fully activated after only two doses of virus. Consequently, analysis of gene expression after additional doses is necessary before definite conclusions about repeat administration of viral vectors can be drawn. This is supported by our data. After a second dose of DF/SeV, expression is significantly reduced by 60 and 490% in mice 7 and sheep, respectively. However, because of the original extremely high gene transfer efficiency the residual gene expression after the second dose is still significantly higher than untransfected controls, or a single dose of non-viral vector. After subsequent doses, however, gene expression drops further leading to very low levels of residual gene expression. In mice these levels are similar to GL67A- Validation of recombinant Sendai virus in sheep U Griesenbach et al mediated expression and repeat administration of SeV does not, therefore, offer an advantage over the cationic lipid GL67A. The latter is the current 'gold-standard' lipid for airway transfection and is currently used by us in clinical trials for CF gene therapy. Moreover, repeat administration of DF/SeV into its natural host (mice) and non-natural host (sheep) models led to similar results.
This study also assessed our understanding of DF/SeV vector delivery to the lungs of large animal models. Thus, (1) we showed that, DF/SeV is not stable in the commonly used Pari-LC Plus jet nebuliser. Although this nebuliser is suitable for aerosolization of lipid/DNA complexes 13 and non-enveloped adeno-associated virus 14 and has been used in gene therapy clinical trials, 15, 16 the shear forces generated appear to destroy the enveloped SeV. The latest generation of vibrating mesh-based single-pass nebulisers, such as the Pari eFlow, will need to be assessed for the delivery of enveloped virus.
(2) DF/SeV was stable in polythylene catheters (100% stability) and the Trudell AeroProbe (approximately 50% stability). The decrease in viability observed with the Aeroprobe was not unexpected as only 40% of viable particles were recovered after aerosolization of helperdependent adenovirus vectors through catheters rated at 8 mm, rising to 80% with 15 mm, respectively. 17 (3) In addition, we were able to compare virus distribution after catheter-based segmental administration and Trudell AeroProbe aerosolization. Delivery by instillation results in patchy expression in the lungs likely due to the uneven distribution and pooling effect from the delivery of a bolus. The AeroProbe catheter has the advantage that it generates an aerosol at the tip of the catheter. This results in a cone-shaped particle stream of aerosol visible to the eye even when viewed through the bronchoscope camera. To target an individual segment, we positioned the Aeroprobe in a small bronchus (with an approximate diameter of o5 mm) leading to that segment and observed that a significant proportion of the aerosol stream impacted on the airway wall close to the catheter tip and collected in a puddle. This resulted in a transgene expression pattern similar to that observed with the instillation delivery and significant spill-over to the adjacent lung segment.
In contrast, when the Aeroprobe was positioned either in the trachea or the main bronchus (approximate diameter of 10 mm), the larger airway diameter reduced the impaction of the aerosol on the airway wall and led to a more even distribution in the lung. The predicted aerosol droplet size generated by this catheter is considerably larger (5-10 mm) than would normally be expected to result in deposition in the terminal bronchioles or alveolar regions. However, intratracheal aerosolization of similar size droplets to the rabbit lung, or of droplets with a mass median aerodynamic diameter of 430 mm in the mouse, has been shown to give deposition to airways of all sizes and even into the alveolar regions 17, 18 suggesting that the droplet size is not so critical when generated intratracheally.
(4) We did not detect any infectious virus shedding 48 h after transfection and were, therefore, able to house treated sheep in outside pens without any specific precautions for operators and waste disposal after this time-point. Before 48 h post-dosing, animals were housed in indoor pens and all waste was autoclaved consistent with guidelines for working with genetically modified organisms.
(5) Administration of DF/SeV-Luc lead to gene expression 3.5 logs above untransfected controls in bronchial biopsies (unpublished data, DF/SeV-Luc: 7918 ± 2634, untransfected: 1.55 ± 0.37 RLU mg À1 protein n¼3), whereas DF/SeV-LacZ transfection only increased b-gal by 1 log compared with control, when quantified with a chemiluminescent reporter gene assay. In cell lysates prepared from lung tissue pieces these differences were even more striking. DF/SeV-Luc administration increased luc expression by 5-logs (unpublished data, DF/SeV-Luc: 21079 ± 6659, untransfected: 0.07 ± 0.006 RLU mg À1 protein n¼3), whereas b-gal was not reliably detectable after DF/SeV-LacZ transfection. For quantification of reporter gene expression in cell lysates luciferase appears to be a more reliable and sensitive reporter gene in sheep lung, consistent with results observed in murine lungs (unpublished data). This is likely due to the red colour of the tissue lysate interfering with the chemiluminescent b-gal assay used in this study.
SeV may not be the vector of choice for gene therapy for lung diseases requiring longer-term expression because expression levels after re-administration of the vector are low because of the induction of potent cellular and humoral immune responses against the virus, although the relative importance of humoral vs cellular immunity in this process is unclear. In addition to neutralising antibodies, activation of cytotoxic T-cells natural killer (NK) cells are activated through interaction of the SeV hemagluttin-neuraminidase (HN) protein with the NK cell receptor NKp46 19 having an important role. The effect of SeV on immune modulation is further highlighted in a study by Komary et al, which showed that SeV-transduced dendritic cells can induce persistent NK and CD4-cell-dependent anti-tumor activity. 20 We have previously shown that SeV administration evokes cellular and humoral immune responses in an animal model and that the level of neutralising antibodies (as measured by in vitro assays) increases after virus re-administration. 7 However, there was no correlation between neutralising antibody levels and residual gene expression (r 2 ¼0.046, P¼0.16). We have also shown that partial T-cell tolerance to SeV infection can be induced in mice after administration of immunodominant CD4 peptide eptiopes, but that a reduction in T-cells does not alter the levels of SeV-neutralising antibodies, or allow for repeat administration of the virus. Although in vitro quantification of neutralising antibodies is frequently undertaken, we do not believe that a single host defence factor will reliably predict efficiency of repeat administration in pre-clinical studies. Our concern about quantification of neutralising antibodies, in part, stems from recent studies showing that (a) adeno-associated virus vector can be re-administered even in the presence of high levels of circulating neutralising antibodies 21 and (b) in vitro neutralization assays fail to predict inhibition by antiviral antibodies in vivo. 22 However, the vector remains one of the most efficient gene transfer agents for the lung. The envelope proteins F (fusion) and HN (hemagglutinin-neuraminidase) are the key factors in determining the high-transfection efficiency to airways. We have, therefore, recently pseudotyped a simian lentiviral vector with the SeV F and HN proteins (F/HN-SIV) 23 and have shown that the virus efficiently transfects mouse airway epithelium in vivo, as well as human air-liquid interface cultures. 24 Moreover, F/HN-SIV-mediated gene expression persists for more than 17 months after a single administration and repeated administration (3 doses) is feasible. 24 It is interesting that the HN-mediated activation of NK cells does not appear to interfere with F/HN-SIV-mediated gene expression. The F/HN-SIV vector may, therefore, be ideally suited for pulmonary gene therapy.
In conclusion, although SeV transduces the airway epithelium of mice and sheep efficiently, and retains comparatively high levels of gene expression after administration of a second dose, these levels drop further following the administration of a third dose at weekly or monthly intervals. Responses to repeat administration of SeV in natural hosts (mice) and non-natural hosts (sheep) are, therefore, similar. We suggest that SeV is not suitable for diseases that require high-level gene expression after repeat administration, but should be strongly considered for lung-related applications requiring a single administration of the gene transfer vector.
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MATERIALS AND METHODS
Virus preparation
The generation and propagation of the recombinant DF/SeV vector carrying a luciferase (DF/SeV-luc) or LacZ (DF/SeV-LacZ) reporter gene or no reporter gene (DF/SeV-empty) was carried out as previously described. 25 The supernatant of LLC-MK2/F7 cells containing infectious particles was subsequently purified, concentrated and stored at -80 1C. Virus titre was determined by infecting LLC-MK2 cells and counting the number of b-gal-expressing cells after X-gal staining or by using an anti-SeV antibody and fluorescent immunohistochemistry. The titre was expressed as CIUs per ml.
Virus stability in delivery devices
PariLC plus. Two nebuliser set-ups were assessed in vitro. (a) Nebuliser with mouth-piece, (b) Nebuliser with attached endotracheal tube used for aerosol delivery to sheep. 5 ml of DF/SeV-LacZ (10 7 CIU ml À1 ) were nebulized using a pressure of 29 psi until run dry (approximately 15 min). Aerosols were collected in a plastic tube. Polythylene endoscopic wash catheter (PEC, Olympus): 5 ml of DF/SeV-LacZ (10 7 CIU ml À1 ) were delivered through the catheter and collected in a plastic tube. Trudell AeroProbe catheter (Trudell Medical International, Ontario, Canada). This is a multi-lumen catheter, with liquid injected down a central lumen and sheared into droplets at the distal tip by high-pressure air travelling down six peripheral lumens. 5 ml of DF/SeV-LacZ (10 7 CIU ml À1 ) were delivered through the AeroProbe and collected in a plastic tube. To quantify virus viability, confluent LLC-MK2 cells grown in six-well plates were transfected in triplicate with appropriate virus dilutions (100 ml/plate). After 1 h cells were washed once with PBS after which 2 ml of MEM+10 foetal bovine serum and 1% penicillin/streptomycin were added. Xgal staining was performed 48 h after transfection. X-gal-positive cells were quantified in each well. Virus not exposed to nebulisers or catheters was used as a positive control and untransfected cells were used as a negative control. Virus titre (CIU ml À1 ) was defined as X-gal positive per ml and % cell viability was calculated.
Preparation of GL67A/DNA complexes A eukaryotic expression plasmid carrying the luciferase reporter gene cDNA (pCIKLux) under the control of the human cytomegalovirus immediate early promoter/enhancer (CMV) was used. Cationic lipid GL67A was supplied by Genzyme Corporation (Framingham, MA, USA) and complexed with DNA as previously described for intrapulmonary administration by nasal 'sniffing' . 26 In vivo gene transfer in mice and sheep
All experiments were carried out with approval of appropriate local Ethics Committees and according to Home Office regulations.
Mice. Female Balb/C mice (6-8 weeks) were anaesthetised with metofane (Medical Developments Australia, Springvale, Australia). For intrapulmonary administration by nasal 'sniffing' a single 100 ml bolus containing either virus (10 8 CIU/mouse or GL67A/DNA complexes (80 mg plasmid DNA complexed to GL67A at a 1:4 lipid:DNA molar ratio) was slowly pipetted onto the nose and the solution was rapidly sniffed into the lungs. At indicated time-points the administration was repeated, or animals were culled and lung tissue retrieved for analysis of luciferase expression.
Sheep. Suffolk Cross ewes, 35-60 kg, were treated with anthelminthic agents before the study began and underwent a preliminary examination involving bronchoscopic visualization and bronchoalveolar lavage of segment right apical under gaseous anaesthesia 1-3 weeks before treatment to confirm absence of pre-existing pulmonary disease. Anaesthetized sheep were maintained in a whole body, negative pressure respirator as described previously. 8 Virus was delivered by means of a bronchoscope, either by (a) instillation to single lung segments via the PEC, (b) by AeroProbe catheter directed at specific locations, or (c) by AeroProbe catheter directed at the whole lung. For instillation to individual lung segments the bronchoscope was wedged within that segment and either 0.67Â10 9 CIU ml À1 of DF/SeV-LacZ (segment right caudal diaphragmatic) or empty vector (DF/SeV-empty (segment left caudal diaphragmatic) instilled in 5 ml PBS. For AeroProbe delivery to individual segments the tip of the AeroProbe was positioned in the lumen at the entrance to the segment, but not wedged, as 50-psi air pressure is required to generate the aerosol. 2Â10 9 CIU ml À1 were delivered in 5 ml PBS. For delivery to the whole lung the AeroProbe was positioned centrally in the trachea, immediately distal to the end of the endotracheal tube and 1.6Â10 9 CIU ml À1 delivered in 24 ml PBS. For duration of expression and repeat dose studies a 7 ml dose of virus containing 5Â10 9 or 1Â10 10 CIU was delivered to each side of the lungs, respectively. With the Aeroprobe catheter positioned far back in the right and left main bronchi the aerosol exposure was focussed in the caudal and ventral diaphragmatic lung segments.
At the indicated time points the temperature of the animal was recorded and blood samples collected for serum and haematology. The sheep were either killed for analysis, anaesthetized as before for repeat administration of virus or anaesthetized and maintained on a positive pressure ventilation system (Harvard Apparatus Model 708) for the collection of bronchial biopsies and bronchial brushings with biopsy forceps (Crocodile Biopsy Forceps, Olympus FB-15K-1, Olympus Keymed, Essex, UK) or cytology brushes (Olympus BC-202D-2010), respectively. Bronchial brushings were collected into PBS and biopsies frozen for luciferase assays. Following euthanasia by lethal injection and exsanguination, the lungs were removed for tissue harvesting. The pulmonary circulation was flushed through the pulmonary artery with 2-3 l of PBS before sampling. bronchoalveolar lavage fluid was collected as for pretreatment sampling but from segment right caudal diaphragmatic. Lung tissues collected post mortem were fixed by perfusion with 2% neutral buffered formalin, 0.2% glutaraldehyde, 2 mm MgCl 2 and 5 mM EGTA pH 8 in 0.1 M phosphate buffer (pH 7.3) and selected segments dissected out for X-gal staining. Alternatively, individual segments were cut transversely into approximately 1-cm thick slices representing upper, middle and lower regions. Individual airways (42 mm diameter) were dissected from the upper region (Airway Upper). Parenchymal samples (containing airways too small to dissect, o2 mm diameter) were derived from the upper (parenchyma upper), middle (M) and lower (L) regions. Finely chopped samples were snap frozen for luciferase assays.
Reporter gene expression
Luciferase assay. Mouse right lungs were placed in 300 ml 1ÂRLB buffer (Promega, Southampton, UK) and homogenized, followed by three freezethaw cycles (À80 1C for 30 min, thawed at room temperature) and centrifugation (10 min at 13 000g av ). Sheep lung tissue (300 mg) or whole-bronchial biopsies were transferred to FastRNA ProGreen matrix tubes (MP Biomedicals, Solon, OH, USA) in 600 ml reporter lysis buffer (RLB; Promega Corp., Madison, WI, USA) and homogenized in a FastPrep Instrument (MP Biomedicals) for 40 s at speed setting 6. Lysates were centrifuged at 13 000 g av / 10 min/4 1C. Supernatant was frozen on dry ice and stored at À80 1C. All supernatants were removed and frozen at À80 1C for luciferase quantification. Luciferase activity was measured in the supernatant using a standard luciferase assay kit (Promega) and the TD-20e luminometer (Turner BioSystems, Sunnyvale, CA, USA) or the Anthos Lucy1 luminometer (Labtech International, East Sussex, UK). b-gal assay in tissue lysate: sheep lung tissue was homogenized (Ultra-Turrax homogeniser Science Lab Houston, TX, USA) in 1ÂRLB buffer by weight (1 ml RLB to 1 g tissue and bronchial biopsies were homogenized by hand using scissors in 120 ml 1ÂRLB buffer. Supernatants from the homogenates were collected after three freeze-thaw cycles (À80 1C for 30 min, thawed at room temperature) and centrifugation (10 min at 13 000g av ). Samples were stored -80 1C b-gal expression was quantified using the Clontech Detection Kit II (BD Biosciences Clontech, Franklin Lakes, NJ, USA). Light emission was measured by the TD-20e luminometer as described above. Protein assay: total protein per sample was determined using the BioRad protein assay kit (BioRad laboratories, Hercules, CA, USA) and luciferase or b-gal activity was expressed as arbitrary relative light units per mg total protein. X-gal staining: lung tissue was stained as described previously. 27 Briefly, fixed sheep tissue was washed three times in detergent (20 min each) and stained in X-gal for up to 48 h at 30 1C. Samples were then washed (2Â20 min in PBS containing 2 mM MgCl 2 ) and then processed into wax for sectioning.
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Virus shedding
Sheep (n¼5) were transfected with DF/SeV-LacZ using whole-lung Trudell AeroProbe administration (10 10 CIU in 24 ml PBS). At 48 h after delivery bronchoalveolar lavage, oral and nasal swabs in PBS and lung tissue samples were collected from two sheep at necropsy. For the remaining three sheep nasal and oral swabs, broncho-alveolar lavage fluid and serum were collected from sheep that were kept alive as part of the 28-day duration study. These samples were analyzed for viable virus particles. Lung tissue was homogenized in PBS and all samples were filtered (0.45 mm) to allow removal of bacteria and fungi. Moreover, filters were first treated with 1 ml of DF/SeV-GFP (10 7 CIU ml À1 ) to minimise DF/SeV-LacZ absorption to the filter during this process. Viable virus particles were then quantified by incubating the samples with LLC-MK2 cells as described above.
To determine assay sensitivity, PBS was 'spiked' with known amounts of virus (7 to 7000 CIU ml À1 ), filtered through a 0.45 mm filter and plated onto LLCMK cells for X-gal staining. The assay was able to detect 1:250 viable virus particles.
Statistical analysis
Statistical analyses were performed by ANOVA or Kruskal-Wallis followed by post-hoc analysis appropriate for parametric and non-parametric data. The null hypothesis was rejected at Po0.05.
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